Download image:

Carla J. DeMuro-Mercon

Senior Research Psychometrician

Carla DeMuro-Mercon has extensive experience in the rigorous development and validation of patient-reported outcome measures for use in clinical trials as well as large-scale epidemiologic and population-based studies. Ms. DeMuro-Mercon has worked to developed measures across a wide span of therapeutic areas including respiratory illness (asthma, COPD, allergic rhinitis, influenza), oncology (non-small cell and small cell lung cancer), Alzheimer's disease, infectious disease (including sexually transmitted disease), sleep disorders, hair loss (male and female), menopausal symptoms, cognition, acne, benign prostatic hyperplasia, diabetes and migraine. Measures have included multiple types of patient-reported outcomes including quality of life, treatment satisfaction, symptom severity, daily event logs, patient diaries, utility measures and other patient-reported outcomes. She has specialized in both the qualitative and quantitative aspects of instrument design and has worked towards creating a clear path from measure development to interpretation.


PhD candidate, Public Health, Walden University; MS, Community Health, Arcadia University; BS (summa cum laude), Applied Computer Science/Communications, Chestnut Hill College.

Latest Publications

Gnanasakthy, A., Sadrick, A., Eghbal-Ahmadi, M., & DeMuro, C. (2014). Promotion of Patient-Reported Outcome Label Claims Based on Nonprimary Endpoints. Therapeutic Innovation & Regulatory Science, 48 (5):557-563.
Clark, M., Simons, C., Haydysch, E., DeMuro, C., & Gnanasakthy, A. (2014). A review of patient-reported outcome orphan drug labels in the United States from January 2006-September 2013: Analysis of evidence for orphan drug PRO label claims. Presented at Presented at ISPOR 19th Annual International Meeting; May 31-June 4, 2014; Montreal, QC, Canada, 2014.
Coles, T., Coon, C., DeMuro, C., McLeod, L., & Gnanasakthy, A. (2014). Psychometric evaluation of the Sheehan Disability Scale in adult patients with attention-deficit/hyperactivity disorder. Neuropsychiatric Disease and Treatment, 10 :887-895.
DeMuro, C., Clark, M., Doward, L., Evans, E., Mordin, M., & Gnanasakthy, A. (2013). Assessment of PRO label claims granted by the FDA as compared to the EMA (2006–2010). Value in Health, 16 (8):1150-1155.
View all publications by Carla J. DeMuro-Mercon (36)


  • Instrument Development and Validation
  • Epidemiology